期刊
CHEMMEDCHEM
卷 7, 期 3, 页码 359-374出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201100585
关键词
aggregation; amyloid proteins; drug design; inhibitors; molecular tweezers; oligomerization; polyphenols
资金
- University of California, Los Angeles (UCLA) Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development
- California Department of Health Services (USA) [07-65798]
- Team Parkinson/Parkinson Alliance (Kingston, USA)
- RJG Foundation (New York, USA) [20095024]
- Cure Alzheimer's Fund (USA)
Abnormal protein assembly causes multiple devastating disorders in the central nervous system (CNS), such as Alzheimers, Parkinsons, Huntingtons, and prion diseases. Due to the now extended human lifespan, these diseases have been increasing in prevalence, resulting in major public health problems and the associated financial difficulties worldwide. The wayward proteins that lead to disease self-associate into neurotoxic oligomers and go on to form fibrillar polymers through multiple pathways. Thus, a range of possible targets for pharmacotherapeutic intervention exists along these pathways. Many compounds have shown different levels of effectiveness in inhibiting aberrant self-assembly, dissociating existing aggregates, protecting cells against neurotoxic insults, and in some cases ameliorating disease symptoms in vivo, yet achieving efficient, disease-modifying therapy in humans remains a major unattained goal. To a large degree, this is because the mechanisms of action for these drugs are essentially unknown. For successful design of new effective drugs, it is crucial to elucidate the mechanistic details of their action, including the actual target(s) along the protein aggregation pathways, how the compounds modulate these pathways, and their effect at the cellular, tissue, organ, and organism level. Here, the current knowledge of major mechanisms by which some of the more extensively explored drug candidates work are discussed. In particular, we focus on three prominent strategies: 1) stabilizing the native fold of amyloidogenic proteins, 2) accelerating the aggregation pathways towards the fibrillar endpoint thereby reducing accumulation of toxic oligomers, and 3) modulating the assembly process towards nontoxic oligomers/aggregates. The merit of each strategy is assessed, and the key points to consider when analyzing the efficacy of possible drug candidates and their mechanism of action are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据